Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.

Abstract

OBJECTIVES:

Systemic anaplastic large-cell lymphoma (sALCL) is a rare hematological malignancy with poor prognosis, which is associated with a significant economic burden. This study aimed to evaluate the cost-effectiveness of brentuximab vedotin (BV) in comparison to conventional chemotherapy in patients with relapsed/refractory sALCL, from a Chinese healthcare perspective.

METHODS:

A partitioned survival model with three health states (progression-free survival, post-progression survival, and death) was adapted to compare BV against chemotherapy. Comparator represented a basket of commonly used chemotherapies in China. Two cohorts in each arm were estimated, representing patients receiving no transplant and autologous stem cell transplant (ASCT) after BV or chemotherapy. Clinical data was obtained from the pivotal phase-II trial (NCT00866047) for BV and also from the literature for a comparator. Resource use items covered drug acquisition and administration; concomitant medications; ASCT; treatment of adverse events; and long-term follow-up. Cost parameters were based on Chinese sources. Outcomes were measured in quality-adjusted life-years (QALYs). Both costs and effects were discounted at 5% according to Chinese guidelines. The impact of uncertainty was evaluated using deterministic and probabilistic sensitivity analyses.

RESULTS:

The incremental cost-effectiveness ratio (ICER) for BV vs. chemotherapy was $9,610 (¥62,084) per QALY in the base case. The main model driver was superior progression-free and overall survival benefits of BV. The ICERs were relatively robust in the majority of sensitivity analyses, ranging around ±10% of the base case. Under the conventional decision thresholds (1-3 times of Chinese per capita GDP), the probability of BV being cost-effective ranged from 56 to 100%. Limitations of the study included the lack of comparative data from the trial and the small and heterogeneous sample due to its disease nature.

CONCLUSIONS:

BV may be a cost-effective treatment vs. chemotherapy in treating relapsed or refractory systemic anaplastic large-cell lymphoma in China.

• Authors: Jia Liu, Lei Zheng, Ling-Hsiang Chuang
• Journal: Journal of medical economics (J Med Econ) 2022 Jan-Dec Vol. 25 Issue 1 Pg. 99-107 ISSN: 1941-837X [Electronic] England
• PMID: 34927526 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Immunoconjugates
• Brentuximab Vedotin

Topics

• Brentuximab Vedotin
• Cost-Benefit Analysis
• Hodgkin Disease
• Humans
• Immunoconjugates (therapeutic use)
• Lymphoma, Large-Cell, Anaplastic (drug therapy)
• Neoplasm Recurrence, Local